NCT07099443 Determinants of the Response to BTK Degraders (BTKd) in Chronic Lymphocytic Leukemia
| NCT ID | NCT07099443 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nantes University Hospital |
| Condition | Chronic Lymphocytic Leukemia |
| Study Type | OBSERVATIONAL |
| Enrollment | 60 participants |
| Start Date | 2025-10-09 |
| Primary Completion | 2039-09-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 60 participants in total. It began in 2025-10-09 with a primary completion date of 2039-09-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the REBELLE cohort - bio-collection is to collect samples from patients with Chronic Lymphocytic Leukemia candidates or those exposed to BTK degraders to evaluate the mechanisms of resistance to these new molecules. To do this, an additional blood or bone marrow sample to those planned in the context of patient care or a residual lymph node biopsy sample will be collected after signing consent.
Eligibility Criteria
Inclusion Criteria: * Patient with CLL candidates ou exposed to BTKd * Patient who has provided informed consent to participate in the study. * Patient covered by a social security health insurance plan Exclusion Criteria: * Minor patients. * Adults under guardianship. * Protected persons.
Contact & Investigator
Anne LOK, MD, PhD
PRINCIPAL INVESTIGATOR
Hospital of Nantes
Frequently Asked Questions
Who can join the NCT07099443 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Lymphocytic Leukemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07099443 currently recruiting?
Yes, NCT07099443 is actively recruiting participants. Contact the research team at anne.lok@chu-nantes.fr for enrollment information.
Where is the NCT07099443 trial being conducted?
This trial is being conducted at Angers, France, Bordeaux, France, Bordeaux, France, Clermont-Ferrand, France and 10 additional locations.
Who is sponsoring the NCT07099443 clinical trial?
NCT07099443 is sponsored by Nantes University Hospital. The principal investigator is Anne LOK, MD, PhD at Hospital of Nantes. The trial plans to enroll 60 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.